Lupin Limited (NSE:LUPIN)
India · Delayed Price · Currency is INR 1,943.80
+3.80 (0.20%)
Oct 20, 2025, 3:29 PM IST
Lupin Revenue
Lupin had revenue of 62.68 billion INR in the quarter ending June 30, 2025, with 11.93% growth. This brings the company's revenue in the last twelve months to 233.76 billion, up 12.40% year-over-year. In the fiscal year ending March 31, 2025, Lupin had annual revenue of 227.08 billion with 13.48% growth.
Revenue (ttm)
233.76B
Revenue Growth
+12.40%
P/S Ratio
3.80
Revenue / Employee
9.74M
Employees
24,006
Market Cap
888.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 227.08B | 26.97B | 13.48% |
| Mar 31, 2024 | 200.11B | 33.69B | 20.25% |
| Mar 31, 2023 | 166.42B | 2.36B | 1.44% |
| Mar 31, 2022 | 164.05B | 12.43B | 8.19% |
| Mar 31, 2021 | 151.63B | -2.12B | -1.38% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Aurobindo Pharma | 320.25B |
| Cipla | 274.80B |
| Zydus Lifesciences | 236.08B |
| Apollo Hospitals Enterprise | 225.51B |
| Glenmark Pharmaceuticals | 134.56B |
| Alkem Laboratories | 133.04B |
| Mankind Pharma | 129.10B |
Lupin News
- 11 days ago - Lupin launches strategic partnership program to expand reach of PrecisionSphere long-acting injectable platform - Business Upturn
- 11 days ago - Lupin shares rally over 3% after announcing $250 million investment in new manufacturing plant - Business Upturn
- 19 days ago - Lupin launches Rivaroxaban for Oral Suspension in the US - Business Upturn
- 19 days ago - Lupin shares jump over 3% after receiving U.S. FDA approval for Rivaroxaban for Oral Suspension - Business Upturn
- 20 days ago - Lupin secures U.S. FDA approval for Rivaroxaban for Oral Suspension - Business Upturn
- 21 days ago - Lupin subsidiary Nanomi B.V. to acquire VISUfarma B.V. for €190 million - Business Upturn
- 25 days ago - Lupin shares edge higher after tentative US FDA approval for HIV drug generic - Business Upturn
- 26 days ago - Lupin gets tentative USFDA approval for HIV treatment drug - Business Upturn